BioCentury
ARTICLE | Clinical News

Gilead reports interim ORR data for idelalisib

June 18, 2013 12:38 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) reported interim data showing twice-daily oral idelalisib led to an overall response rate (ORR), the primary endpoint, of 53.6% in the Phase II Study 101-09 to treat refractory indolent non-Hodgkin's lymphoma (NHL). In 125 patients in the single-arm, open-label trial, there were five complete responses, 60 partial responses and two minor responses, plus 46 cases of stable disease. The median progression-free survival (PFS) was 11.4 months, and 89% of patients experienced "some shrinkage" in lymph node size. Data are slated to be presented on Thursday at the Malignant Lymphoma meeting in Lugano. ...